10X Genomics Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? 10X Genomics Inc trades at $67.59 (market cap $8.55B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $44.53. The key difference: 10X Genomics Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| TXG | VNQI | |
|---|---|---|
Market Cap | $8.55B | — |
Sector | Health | — |
52-Week High | $67.29 | $50.76 |
52-Week Low | $11.34 | $43.26 |
Enterprise Value | $8.08B | — |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $44.95, down 0.71% with a bearish technical signal. The ETF focuses on international real estate across 30+ countries, offering a higher dividend yield than domestic peers but showing lower recent returns. Moving averages indicate selling pressure while oscillators remain neutral. Recent news highlights institutional selling and comparisons with competing real estate ETFs.
The outlook remains cautious due to technical weakness and international real estate market volatility. Investment opportunity lies in global diversification and attractive dividend yield, but risks include currency exposure and underperformance versus U.S. real estate. The bearish technical setup suggests near-term pressure despite neutral fundamental positioning.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →